MECP2 and atypical Rett syndrome: Understanding the entire picture of how MECP2 mutation results in the clinical phenotype of Rett syndrome through omics will allow us to design and test molecular biomarkers for response to these gene therapy strategies, and may allow the development of personalized medicine strategies to aid in the successful completion of clinical trials involving gene therapy.